Judge allows Neurim to seek additional damages in patent suit over insomnia drug
Intellectual Property 2020-12-14 3:18 pm | Sydney
Neurim Pharmaceuticals can seek limited additional damages in a patent infringement case relating to its insomnia drug Circadin, after a judge granted a mid-trial bid to amend its pleadings against Generic Partners and Apotex.
For information on rights and reprints, contact subscriptions@lawyerly.com.au